Lannett has bolstered its biosimilar insulin co-development pact with China’s HEC Group in the US, adding a biosimilar candidate to Novo Nordisk’s NovoLog (insulin aspart) which is currently in development and for which the US-based firm will help manage the remaining clinical and regulatory steps.
The NovoLog biosimilar, which Lannett described as a “distinct product opportunity,” joins the firms’ biosimilar Lantus (insulin glargine) candidate for...






